Compare ARVN & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | CTKB |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 652.1M |
| IPO Year | 2018 | 2021 |
| Metric | ARVN | CTKB |
|---|---|---|
| Price | $12.24 | $5.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 5 |
| Target Price | ★ $18.14 | $5.70 |
| AVG Volume (30 Days) | 792.5K | ★ 955.6K |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $312,300,000.00 | $196,828,000.00 |
| Revenue This Year | $11.17 | $0.08 |
| Revenue Next Year | N/A | $5.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.86 | N/A |
| 52 Week Low | $5.90 | $2.37 |
| 52 Week High | $20.38 | $6.93 |
| Indicator | ARVN | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 54.26 |
| Support Level | $11.88 | $5.37 |
| Resistance Level | $12.79 | $6.04 |
| Average True Range (ATR) | 0.53 | 0.25 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 68.02 | 44.54 |
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.